Merck hands its hep C combo to the FDA with sights on Gilead and AbbVie

Merck hands its hep C combo to the FDA with sights on Gilead and AbbVie
The U.S. pharma giant submitted a one-tablet combination of grazoprevir and elbasvir, two agents designed to halt hep C's ability to replicate itself and survive in the body. Merck is angling for approval in patients with genotypes 1, 4 and 6 of the …
Read more here.

Painkiller addiction spawns new hepatitis C threat
In the CDC study of disease patterns, the number of new hepatitis C infections among people age 30 and under in Kentucky, Tennessee, Virginia and West Virginia rose 364 percent from 2006 to 2012; three-quarters of the cases involved injected-drug use …
Read more here.

Research Shows Hepatitis C Illness, Death Increasing in Arkansas
LITTLE ROCK, AR (Arkansas.gov) – Illness and death due to Hepatitis C (Hep C) infection is increasing in Arkansas, according to new research published in the May 2015 issue of the Journal of the Arkansas Medical Society. The research, conducted by …
Read more here.

Maine CDC urges baby boomers to get hepatitis C test
Most people who have hepatitis C do not realize they have the virus; Between 20 percent and 30 percent of people with hepatitis C experience symptoms. Some of these individuals can live for decades without ever feeling sick or showing symptoms, but if …
Read more here.

Police: Robber threatened guard with dirty syringe, Hepatitis C
When a security guard stopped Eaton in the parking lot, Eaton mentioned there was a syringe in his pocket and that he might have Hepatitis C. He then fled. Police posted a picture of the two men the next day on the department's Facebook page, the …
Read more here.

Minnesota prison inmates sue to gain access to costly hepatitis C medications
Two inmates are suing the Minnesota Department of Corrections seeking access to costly drug treatments for hepatitis C, a serious liver condition that in many cases can be cured with a new generation of medications. Filed in federal court this month …
Read more here.

Stocks to Watch: JP Morgan, GameStop, Altera
Merck MRK +0.40% & Co. submitted a New Drug Application to the U.S. Food and Drug Administration for an experimental drug combination for treating certain chronic hepatitis C patients. In addition, Merck and Amgen Inc.AMGN -1.96% expanded their …
Read more here.

North Shore lawmakers request budget amendments for local projects
Tarr also earmarked $ 80,000 for a Hepatitis C program at the North Shore Health Project in Gloucester, and $ 60,000 for a program to protect the North Shore's saltwater clam population from invasive green crabs. Sen. Kathleen O'Connor-Ives, D …
Read more here.

Hepatitis C treatment may be cost-effective in prisons in England
Reducing the duration of direct-acting antiviral treatment for hepatitis C will make treatment for people in prison in England highly cost-effective, and could provide an important opportunity for providing access to hepatitis C treatment for people …
Read more here.

Consumers Sue Anthem for Denying Coverage for a Gilead Hepatitis C Drug
The controversy over the new crop of hepatitis C treatments has taken yet another turn as consumers are starting to file lawsuits against insurers that deny them access to the medicines. Over the past two weeks, two different women alleged that Anthem …
Read more here.

Pharmalot.. Pharmalittle.. As the Weekend Nears: We're Catching up on Merck
Merck submitted a new drug application to the FDA for an experimental drug combination to treat certain chronic hepatitis C patients, according to The Wall Street Journal. The combined tablet, which demonstrated a 95% cure rate in a late-stage study …
Read more here.

Market Overview: Hepatitis C Therapeutics in Major Developed Markets to 2019
The Report Hepatitis C Therapeutics in Major Developed Markets to 2019 – Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape provides information on pricing, market analysis, shares, forecast, and …
Read more here.


Leave a Reply